Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M

Alaunos Therapeutics, Inc.

ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
Liver weight reduced 43% (p<0.0001); lower ALT, AST, ALP and improved histology in treated animals.
Favorable body composition shift: fat -44.6% (grams), lean +17.2% as % body weight (high dose).
Cash and cash equivalents $0.354M as of March 31, 2026; runway into Q2 2026, needs additional financing.
Data from non-GLP mouse studies only; ALN1003 has not been tested in humans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.